

# Network dynamics driving cancer metastasis: from design principles to therapeutic approaches

Mohit Kumar Jolly, PhD

Assistant Professor,

Centre for BioSystems Science and Engineering  
Indian Institute of Science (IISc), Bangalore, India



[mkjolly@iisc.ac.in](mailto:mkjolly@iisc.ac.in)



July 29, 2022


International Summer Institute on Network Physiology (ISINP) 2022

# Metastasis : the cause of 90% of all cancer deaths



**Metastasis has extremely high attrition (> 99.9%) rates.**


# What traits cells need to successfully metastasize?




We need a **dynamic and systems-level understanding** of the process to identify how cells alter these multiple traits together

# Phenotypic plasticity and non-genetic heterogeneity


Cellular/Phenotypic plasticity:  
Ability of cells to switch their  
phenotype/behavior  
reversibly in response to  
environmental conditions




- Cancer stem cell / induced pluripotent cancer cell
- Dedifferentiated cell
- Differentiated cancer cells




# Open questions about plasticity & heterogeneity in cancer



- How many states can cancer cells exist in?
- How do they switch among these states?
- How do they coordinate behavior among these different axes?
- Can we suggest ways to control plasticity and heterogeneity in a dynamic evolving system?



# Acknowledgements



S C Tripathi  
Samir Hanash  
S A Mani



A Rangarajan  
Ramray Bhat  
Adithya Chedere  
Saurav Kumar



Jason A Somarelli  
Andrew Armstrong



Tamal Das  
Basil Thurakkal



Rik Thompson  
Sugandha Bhatia



Pritha Ray  
Ajit Dhadve



Ravi Salgia  
Prakash Kulkarni



Sandeep Singh  
Kavya Vipparthi



Herbert Levine  
Jose N Onuchic  
Shubham Tripathi  
Wen Jia  
Federico Bocci



Kishore Hari  
Sarthak Sahoo  
Maalavika Pillai  
Lakshya Chauhan  
Gubbala Udayram  
Paras Jain  
Atchuta S Duddu  
Divyoj Singh  
Susmita Mandal  
Subbalakshmi A R  
Srinath Muralidharan



Partha Sharthi Dutta  
Sudipta Sinha  
Sukanta Sarkar



Caterina La Porta  
Stefano Zapperi  
Franc Font-Clos




Oncologists  
Clinicians  
Mathematicians  
Physicists  
Chemists  
Engineers




MHRD



# EMT/MET: The engine of metastasis



Adhere to neighbors  
Do NOT migrate or invade  
**Epithelial (E)**




Do NOT adhere to neighbors  
Migrate and invade  
**Mesenchymal (M)**




Mesenchymal-to-Epithelial  
Transition (MET)

Secondary tumor




Epithelial-to-Mesenchymal  
Transition (EMT)

Primary tumor







# Role of EMT in cancer metastasis (2002 – 2012)




Thiery JP, Nat Rev Cancer 2002



Kalluri & Weinberg, J Clin Invest 2009




Lee et al. J Cell Biol 2006




Scheel & Weinberg, Semin Cancer Biol 2012

# Is EMT/MET a binary process?




Mani *et al.*  
PNAS 2007




# Network that controls EMT/MET

→ Transcriptional activation  
 —| Transcriptional repression  
 - - -| miR-mediated repression

**E**




I (HGF, NF-κB, Wnt, Notch, p53, TGF-β, HIF1α)



**M**


- Each arrow/bar indicates a quantitative input-output relationship.
- Such models have been extensively built for simpler microorganisms.
- Can we decode the emergent properties of these nonlinear interactions?

# Mathematical model formulation



Lu\*, Jolly\* *et al.* PNAS 2013

I (HGF, NF- $\kappa$ B, Wnt, Notch, p53, TGF- $\beta$ , HIF1 $\alpha$ )



Production

Degradation

miR regulation

TF regulation

$$\frac{d\mu_{200}}{dt} = g_{\mu_{200}} H^S(Z, \lambda_{Z, \mu_{200}}) H^S(S, \lambda_{S, \mu_{200}}) - m_Z Y_\mu(\mu_{200}) - k_{\mu_{200}} \mu_{200} \quad \text{miR-200}$$

$$\frac{dm_Z}{dt} = g_{m_Z} H^S(Z, \lambda_{Z, m_Z}) H^S(S, \lambda_{S, m_Z}) - m_Z Y_m(\mu_{200}) - k_{m_Z} m_Z \quad \text{ZEB mRNA}$$




$$\frac{dZ}{dt} = g_Z m_Z L(\mu_{200}) - k_Z Z \quad \text{ZEB}$$

$$\frac{d\mu_{34}}{dt} = g_{\mu_{34}} H^S(Z, \lambda_{Z, \mu_{34}}) H^S(S, \lambda_{S, \mu_{34}}) - m_S Y_\mu(\mu_{34}) - k_{\mu_{34}} \mu_{34} \quad \text{miR-34}$$


$$\frac{dm_S}{dt} = g_{m_S} H^S(S, \lambda_{S, m_S}) H^S(I, \lambda_{I, m_S}) - m_S Y_m(\mu_{34}) - k_{m_S} m_S \quad \text{SNAIL mRNA}$$

$$\frac{dS}{dt} = g_S m_S L(\mu_{34}) - k_S S \quad \text{SNAIL}_{12}$$


# Model prediction: EMT is NOT binary




**Hybrid E/M**  
Adhere AND  
migrate collectively



I (HGF, NF- $\kappa$ B, Wnt, Notch, p53, TGF- $\beta$ , HIF1 $\alpha$ )



# Mathematical modeling for EMT dynamics




## Predictions from mathematical model:


1. Cells can stably exist in hybrid E/M state
2. Isogenic cells can exist in different EMT states
3. Cells can 'spontaneously' switch their states

Lu\*, Jolly\* *et al.* PNAS 2013


## Experimental validation:




H1975, T=0






H1975, T=2 months



George\*, Jolly\* *et al.* Cancer Res 2017






Jolly *et al.* Oncotarget 2016






Ruscetti *et al.* Oncogene 2016

# Hybrid E/M phenotype(s) seen in other math models too




Xing *et al.* Biophys J 2013  
 Steinway *et al.* NPJ Sys Biol Appl 2015  
 Hong *et al.* PLoS Comp Biol 2015  
 Jolly *et al.* Oncotarget 2016  
 Huang *et al.* PLoS Comp Biol 2017  
 Font-Clos *et al.* PNAS 2018  
 Silveira *et al.* FEBS J 2019  
 Hari *et al.* NPJ Sys Biol Appl 2020

# Hybrid E/M phenotype(s): 'fittest' for metastasis?



## Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells


Cornelia Kröger<sup>a</sup>, Alexander Afeyan<sup>a,b</sup>, Jasmin Mraz<sup>a,c</sup>, Elinor Ng Eaton<sup>a</sup>, Ferenc Reinhardt<sup>a</sup>, Yevgenia L. Khodor<sup>d</sup>, Prathapan Thiru<sup>a</sup>, Brian Bierie<sup>a</sup>, Xin Ye<sup>a,e</sup>, Christopher B. Burge<sup>d</sup>, and Robert A. Weinberg<sup>a,f,g,1</sup>




- Jolly *et al.* J R Soc Interface 2014
- Grosse-Wilde *et al.* PLoS One 2015
- Bierie *et al.* PNAS 2017
- Pastushenko *et al.* Nature 2018
- Kroger *et al.* PNAS 2019
- Lu & Kang, Dev Cell 2019
- Pastushenko *et al.* Nature 2021




# From EMT (2002-2012) to EMP (Epi-Mes Plasticity; 2013-now)



Lu<sup>#</sup>, Jolly<sup>#</sup> *et al.* PNAS 2013




Nieto *et al.* Cell 2016



	Epithelial tumor cells	Early hybrid EMT state	Hybrid EMT state	Late hybrid EMT state	Mesenchymal tumor cells
Proliferation	+++++	++++	+++	++	+
Invasion	+	++	+++	++++	+++++
Plasticity	+	++	+++	++++	++
Stemness	+	+++	+++	+++	+++
Metastasis	+	++++	++++	++	+

Pastushenko & Blanpain, Trends Cell Biol 2019  
 Pastushenko *et al.* Nature 2018





## Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells

Cornelia Kröger<sup>a</sup>, Alexander Afeyan<sup>a,b</sup>, Jasmin Mraz<sup>a,c</sup>, Elinor Ng Eaton<sup>a</sup>, Ferenc Reinhardt<sup>d</sup>, Yevgenia L. Khodor<sup>d</sup>, Prathapan Thiru<sup>a</sup>, Brian Bierie<sup>a</sup>, Xin Ye<sup>a,e</sup>, Christopher B. Burge<sup>d</sup>, and Robert A. Weinberg<sup>a,f,g,1</sup>



Yu *et al.* Science 2013  
 Kroger *et al.* PNAS 2019

# Clinical relevance of hybrid E/M phenotype(s)




Single-cell migration is very rare, if any, in cancer

Co-expression of ZEB1 and membranous E-cad - a 'partial EMT' status of 'tumor buds'








# Ongoing questions...

Why are hybrid E/M cells more plastic than E, M?




# EMP networks largely contain two “teams”



Huang *et al.* PLoS Comp Biol 2017  
 Jia *et al.* Phys Biol 2019  
 Font-Clos *et al.* PNAS 2018  
 Silveira *et al.* FEBS J 2019; JRSI 2020


- Nodes: Epithelial, Mesenchymal, Input/output (Signal/Effector)
- Edges: Activation, Inhibition
- Mostly activation within a “team”, but inhibition across the two “teams”

# Presence of teams is specific to EMP networks




22N 82E

22N 82E  
Adjacency Matrix






22N 82E  
Influence Matrix









$$Infl = \frac{\sum_{l=1}^{lmax} Adj_{max}^l}{lmax}$$

$$G_{IJ} = \frac{\sum_{i \in I, j \in J} Infl_{ij}}{n_{IJ}}$$

$$G_S = \sum_{i, j \in \{1,2\}} |G_{ij}|$$




# EMP networks give rise to two types of states





Which phenotypes (E, M, hybrid) are more frustrated or coherent?

# Terminal states (E, M) more stable than hybrid E/M



Terminal state more coherent, frequent; less frustrated than hybrid







author

All happy families are alike; each unhappy family is unhappy in its own way.


-Leo Tolstoy

# “Teams” stabilize terminal states (E, M) specifically






# Summary (Teams in EMP networks)



“Teams” shape the landscape enabling higher plasticity and heterogeneity of hybrid E/M phenotypes



Hari *et al.* bioRxiv 2021: 472090



Kishore Hari


# 'Teams' seen in other cell-state switching networks?

I (HGF, NF-κB, Wnt, Notch, p53, TGF-β, HIF1α)




Artwork Credit: Atchuta S Duddu

Lu\*, Jolly\* *et al.* PNAS 2013



Sahoo\*, Singh\* *et al.* J Clin Med 2020



Small Cell Lung Cancer (SCLC)


Chauhan\*, Ram\* *et al.* eLife 2021



**Divyoj Singh**  
(BS/MS, IISc, Phy)




**Sarthak Sahoo**  
(BS/MS, IISc, Bio)



Proliferative-invasive switch in melanoma

Pillai & Jolly, iScience 2021

# Why do 'teams' exist?




33 nodes, 357 edges - **SCLC**


**Offer robustness** (Deletion of 345 out of 357 edges – one at a time – have minimal effect on SCLC cell states)

This network gave rise to 4 states, each with ~25% frequency.

What if we delete an edge (in silico CRISPR)?






# Why do 'teams' exist?



33 nodes, 357 edges - **SCLC**






What if we shuffle edges in the entire network (thus breaking teams)?





**Allow limited number of cell-states**  
 (“Controlled enthusiasm”)

# Why do 'teams' exist?

Couple the axes of plasticity: EMP and drug resistance in ER+ breast cancer



EMT can drive resistance to tamoxifen





Tamoxifen resistance can drive EMT






Sarthak Sahoo

# Suggesting combinatorial therapies for ER+ breast cancer

A



Sahoo *et al.*  
NAR Cancer 2021



B



Model predictions currently undergoing experimental validation

# Summary

- **Multistable** dynamics of underlying networks driving cell-state switching

⇒ Phenotypic plasticity


⇒ Non-genetic heterogeneity

- ‘Design principles’ of such networks:

1. “**Teams**” exist in multiple such networks
2. “**Teams**” offer canalization of phenotypes

- These networks can explain **adaptive, heterogeneous response to drug treatment**


- These networks as platforms to predict combination and sequence of therapies?



Pillai & Jolly, *iScience* 2021





Chauhan\*, Ram\* *et al.* *eLife* 2021



Hari *et al.* *bioRxiv* 2021: 472090

# Dynamical vs. Static hallmarks of Cancer



Mani *et al.*  
PNAS 2007

Cancer is a complex, dynamic, adaptive system  
(and therefore needs to be looked at such).

Math models, coupled with experimental data, have steered our understanding of such systems (weather predictions, finance etc.)



# Acknowledgements: Cancer Systems Biology Lab



**Any questions/comments/  
suggestions welcome!**

**[mkjolly@iisc.ac.in](mailto:mkjolly@iisc.ac.in)**

**Background of CSB members**  
Biotechnology, Engineering (Electrical,  
Mechanical), Bioinformatics, Physics,  
Mathematics, Biology, Chemistry